Here are the Form 4 insider transactions from Nektar Therapeutics (NKTR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NKTR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NKTR filings page.
NEKTAR THERAPEUTICS director Roy A. Whitfield received a 2,000-share restricted stock unit award and a stock option grant covering 4,000 shares on September 23, 2026. The RSUs vest in full one year following that date; the options vest in substantially equal monthly installments over the one-year period beginning that date, have a $57.66 exercise price and expire September 22, 2034. His reported direct common-stock holdings after the transactions were 16,417 shares. Reported indirect holdings were 3,434 shares by the Whitfield Family 2020 Trust and 1,334 shares by Family Trust. No Rule 10b5-1 plan is reported for the transactions.
NEKTAR THERAPEUTICS director Greer R. Scott received grants of 2,000 restricted stock units (RSUs) and 4,000 stock options on September 23, 2026. The RSUs vest in full one year following September 23, 2026; the options vest in substantially equal monthly installments over the one-year period beginning September 23, 2026, have a $57.66 exercise price and expire September 22, 2034. The reported security amounts reflect the one-for-fifteen reverse stock split effected on June 8, 2025.
Nektar Therapeutics director Robert Chess received grants of 2,000 restricted stock units and 4,000 stock options on September 23, 2026. His direct common-stock holdings following the RSU award were 19,019 shares. Each RSU represents a contingent right to receive one common share upon vesting, and the award vests in full one year following September 23, 2026.
The options have a $57.66 exercise price, vest in substantially equal monthly installments over the one-year period beginning September 23, 2026, and expire September 22, 2034. The report also lists 140 shares held by his son; Chess disclaims beneficial ownership of those shares. No Rule 10b5-1 plan is reported.
NEKTAR THERAPEUTICS director Diana Brainard reported two equity awards on September 23, 2026: 2,000 restricted stock units (RSUs), representing contingent rights to common shares, and options for 4,000 common shares. The RSUs vest in full one year following September 23, 2026; the options vest in substantially equal monthly installments over the one-year period beginning on September 23, 2026, at a $57.66 exercise price, and expire September 22, 2034. Her reported direct common-stock holdings after the RSU award were 3,904 shares; the reported post-award amount for the options was 4,000. No Rule 10b5-1 plan is reported.
NEKTAR THERAPEUTICS director Jeffrey Robert Ajer received 2,000 restricted stock units and an option covering 4,000 common shares on September 23, 2026. The reported direct common-stock position following the RSU award was 4,277 shares. Each RSU represents a contingent right to one common share upon vesting.
The RSUs vest in full one year following September 23, 2026; the option vests in substantially equal monthly installments over the one-year period beginning that date. The option has a $57.66 per-share exercise price and expires September 22, 2034. The reported securities amounts reflect the one-for-fifteen reverse stock split effected June 8, 2025.
NEKTAR THERAPEUTICS (NKTR) reported that Chief R&D Officer Jonathan Zalevsky sold 186 shares of common stock on August 18, 2026 at a weighted-average price of $71.98 per share. The sale was made solely to cover required tax withholding upon RSU vesting and is not a discretionary trade. After this sale, he holds 9,570 shares of NKTR common stock directly.
NEKTAR THERAPEUTICS (NKTR) reported that President & CEO and director Howard W. Robin sold 418 shares of common stock on 2026-08-18 at a weighted average price of $71.98 per share, in trades executed between $71.78 and $72.49. According to the company’s disclosure, these shares were sold to cover required tax withholding obligations arising from the vesting of Robin’s RSUs and did not represent a discretionary trade. After this sale, Robin held 54,627 shares directly, and an additional 28 shares were reported as indirectly owned by his spouse.
Nektar Therapeutics reported that Chief R&D Officer Jonathan Zalevsky received a grant of stock options covering 16,500 shares of common stock at an exercise price of $15.1500 per share, expiring on 2032-12-12. These options were granted on December 13, 2024 under the 2017 Amended and Restated Performance Incentive Plan with both performance-based and time-based vesting. The Organization and Compensation Committee determined on July 23, 2026 that the performance condition was satisfied, and the options vested on July 24, 2026, subject to continued monthly pro-rata time-based vesting over five years from the grant date.
Howard W. Robin, President & CEO of Nektar Therapeutics, reported an acquisition of 57,200 stock options linked to common stock. These options were granted on December 13, 2024 under the 2017 Amended and Restated Performance Incentive Plan, have a $15.15 exercise price, and expire on December 12, 2032. The Organization and Compensation Committee determined on July 23, 2026 that the performance-based vesting requirement was satisfied and stated that the options vested on July 24, 2026, while time-based vesting continues on a monthly pro-rata basis over five years from the grant date.
Nektar Therapeutics’ Chief R&D Officer, Jonathan Zalevsky, sold 5,681 shares of Common Stock in an open-market transaction at $70.00 per share. After this sale, he directly holds 9,756 shares. The sale was executed on June 30, 2026 and was made pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026.
Nektar Therapeutics President & CEO Howard W. Robin reported open-market sales of 20,000 shares of common stock over two days in mid-June 2026. On June 16, 2026, he sold 5,303 shares at $59.97 and 4,697 shares at $60.71. On June 17, 2026, he sold 5,500 shares at $60.81 and 4,500 shares at $61.65. A footnote states that at least one transaction was made under a Rule 10b5-1 trading plan adopted on March 13, 2026, indicating the sales were pre-arranged. After these transactions, Robin directly owns 55,045 Nektar shares, and an additional 28 shares are held indirectly by his spouse.
Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky sold 5,538 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $60.71 per share on June 15, 2026, in multiple trades between $60.06 and $61.36.
After this sale, Zalevsky directly holds 15,437 shares of Nektar Therapeutics common stock. The transaction was carried out under a Rule 10b5-1 trading plan that he adopted on March 13, 2026, indicating the sale was pre-arranged rather than timed discretionarily.
Nektar Therapeutics' Chief R&D Officer Jonathan Zalevsky reported a small share sale primarily for tax purposes. On May 19, 2026, he sold 199 shares of common stock at a weighted average price of $65.51 per share to cover required tax withholding obligations linked to vesting restricted stock units. The filing states this did not represent a discretionary trade. Following the transaction, he directly held 20,975 shares of Nektar Therapeutics common stock.
Nektar Therapeutics President & CEO Howard W. Robin reported a small tax-related share sale. On this Form 4, he sold 444 shares of common stock at a weighted average price of $65.51 per share to cover required tax withholding obligations from vesting RSUs, which the company notes was not a discretionary trade.
After the sale, Robin directly holds 75,045 shares of Nektar common stock and has an additional 28 shares reported as indirectly owned through his spouse. The filing reflects routine equity compensation and related tax settlement rather than a change in his overall investment stance.
NEKTAR THERAPEUTICS Chief R&D Officer Jonathan Zalevsky sold 180 shares of common stock on February 18, 2026 to cover required tax withholding obligations tied to vesting RSUs, and this was not a discretionary trade. The weighted average sale price was $73.00 per share, and he held 21,174 shares directly after the transaction.
Nektar Therapeutics President & CEO Robin Howard W reported an open-market sale of 423 shares of common stock on February 18, 2026 at a weighted average price of $73.00 per share. According to the disclosure, these shares were sold to cover required tax withholding obligations related to vesting restricted stock units, and the filing notes this was not a discretionary trade. After the transaction, he directly held 75,489 shares of common stock, with an additional 28 shares held indirectly by his spouse.
Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky reported a planned stock sale under a pre-arranged Rule 10b5-1 trading plan. On January 20, 2026, he sold 3,867 shares of Nektar common stock at a weighted average price of $35.67 per share, through multiple trades within a price range of $35.17 to $36.23. After this transaction, he directly held 21,354 shares of Nektar common stock.
Nektar Therapeutics reported equity awards to its President & CEO and director on December 22, 2025. The executive received 21,667 shares of common stock through a grant of restricted stock units (RSUs) at a stated price of $0. Each RSU converts into one share of common stock as it vests.
The RSUs vest over four years from the grant date in substantially equal quarterly installments, conditioned on continued service. The filing shows the executive beneficially owning 75,912 shares directly after the transaction and 28 shares indirectly through a spouse. In addition, the executive was granted 86,667 stock options with an exercise price of $43.48, expiring on December 21, 2033, which vest over four years in substantially equal monthly installments based on continued service.
Nektar Therapeutics reported insider equity activity for its Chief R&D Officer on a Form 4. On November 21, 2025, the officer acquired 2,666 shares of common stock at $0 as restricted stock units vested under the company’s 2017 Performance Incentive Plan, after the compensation committee determined the performance-based condition had been met.
On November 25, 2025, the officer sold 1,157 shares of common stock at a weighted average price of $54.28, solely to cover tax withholding obligations from the RSU vesting, and not as a discretionary trade. Following these transactions, the officer directly held 18,971 shares of common stock. In addition, a stock option for 4,766 shares with a $281.25 exercise price, originally granted in 2020 under the same plan, also became fully vested on November 21, 2025.
Nektar Therapeutics (NKTR) Chief Legal Officer Mark A. Wilson reported equity award activity. On 11/21/2025, he acquired 1,903 shares of common stock through vesting of previously granted restricted stock units under the company’s 2017 Performance Incentive Plan, following the Compensation Committee’s determination on November 20, 2025 that the performance conditions were met. After this, he beneficially owned 22,215 shares, including shares held in the employee stock purchase plan.
On 11/25/2025, he sold 630 shares to cover tax withholding obligations related to the RSU vesting, leaving 21,585 shares held directly. He also received a grant of 3,400 stock options on 11/21/2025 with an exercise price of $281.25 per share, vesting after the performance-based condition was determined to be satisfied and subject to time-based vesting through December 17, 2028.
Nektar Therapeutics (NKTR) reported insider activity by President & CEO and director Mark A. Wilson. On 11/21/2025, he acquired 7,110 shares of common stock at $0 following the vesting of previously granted restricted stock units. On 11/25/2025, he sold 2,207 shares at a weighted average price of $54.28 to cover tax withholding obligations related to this vesting, which the filing notes was not a discretionary trade. After these transactions, he directly held 54,245 shares of common stock and indirectly held 28 shares through his spouse. In addition, 12,170 stock options with an exercise price of $281.25, expiring on 12/17/2028, vested on 11/21/2025.